This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stasko, J. Articles by Kubisz, P. Search for Related Content PubMed Articles by Stasko, J. Articles by Kubisz, P. Social Bookmarking                         What's this?

Some Hemostatic Changes During the Course of Hemodialysis in Patients with Erythropoietin Treatment

Ján Stako, M.D.

Departments of Hematology and Transftisiology, University Hospital, Martin, Slovakia

Stanislav Funiak, M.D., Ph.D.

Department of Internal Medicine, University Hospital, Martin, Slovakia

Sona Funiaková, M.D.

Department of Internal Medicine, University Hospital, Martin, Slovakia

Mária Peterková, M.D.

Department of Internal Medicine, University Hospital, Martin, Slovakia

Jela Ivanková, R.N.D.

Departments of Hematology and Transftisiology, University Hospital, Martin, Slovakia

Pavol Makovick, M.D.

Department of Internal Medicine, University Hospital, Martin, Slovakia

Peter Kubisz, M.D., D.Sc.

Departments of Hematology and Transftisiology, University Hospital, Martin, Slovakia

The recombinant human erythropoietin (rHuEPO), an effective agent in the treatment of renal anemia, can predispose chronic uremic patients to thrombotic events with regular hemodialysis (HD). It has been proposed that increased release of tissue plasminogen activator (t-PA) from endothelial cells, together with consumption of plasminogen activator inhibitor-1 (PAI- 1), is likely to be a leading cause of enhanced fibrinolytic activity (FA) during HD. In our study, rHuEPO-treated patients manifested PAI-1 Ag (antigen) plasma levels that were significantly augmented after HD, suggesting FA inhibition during the HD session. The elevated predialysis beta-thromboglobulin (BTG) and platelet factor-4 (PF-4) plasma levels were increased in rHuEPO-treated patients during HD; the platelet protein levels were simultaneously decreased in the control group. Both findings reflect decreased FA and greater activity of platelets in the course of HD with administration of rHuEPO and a possible correlation of these mechanisms with the questioned prothrombotic performance of rHuEPO. Key Words: Erythropoietin—Hentodiatysts—Fibrinotytic activity—Platelet proteins.

Clinical and Applied Thrombosis/Hemostasis, Vol. 3, No. 2, 141-143 (1997)
DOI: 10.1177/107602969700300214


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?